GEHC GE HealthCare Technologies Inc. logo

GEHC GE HealthCare Technologies Inc.

Healthcare
$64.23-0.16%ClosedMarket Cap: $29.22B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

19.85

PEG

P/B

2.75

P/S

1.46

EV/EBITDA

11.83

DCF Value

$159.86

FCF Yield

5.2%

Div Yield

0.2%

Margins & Returns

Gross Margin

42.5%

Operating Margin

12.5%

Net Margin

7.5%

ROE

14.8%

ROA

4.1%

ROIC

6.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$5.13B$389.0M$
Q4 null$4.67B$184.0M$
FY null$20.63B$2.08B$
Q3 null$5.14B$446.0M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$83.27

Target (Median)

$85.00

Target Range

$65.00 - $105.00

3 Strong Buy10 Buy7 Hold1 Sell0 Strong Sell
UBSNeutral
2026-05-21
CitigroupNeutral
2026-04-30
JP MorganNeutral
2026-04-30
Goldman SachsNeutral
2026-04-30
Evercore ISI GroupOutperform
2026-04-30

Trading Activity

Insider Trades

View All
Rackliffe Philipofficer: CEO, AIS
SellTue May 19
Bankes Jeannetteofficer: CEO, Patient Care Solutions
SellTue May 19
Hochman Rodney Fdirector
BuyWed May 13
Yang Watkin Phoebe L.director
BuyMon May 11
Yang Watkin Phoebe L.director
SellMon May 11

Congress Trades

View All
Ro KhannaBuy
Wed May 13
Terri SewellSell
Tue Apr 21
Warren DavidsonSell
Thu Mar 26

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

Beta

0.87

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Peers